Author:
Rottman James B,Smith Tammy L,Ganley Kenneth G,Kikuchi Toyoko,Krueger James G
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Molecular Biology,Pathology and Forensic Medicine
Reference36 articles.
1. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, Menter A, Lowe NJ, Krueger G, Brown MJ, Weiner RS, Birkhofer MJ, Warner GL, Berry KK, Linsley PS, Krueger JG, Ochs HD, Kelley SL, and Kang S (1999). CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 103: 1243–1252.
2. Abu Elmagd K, Van Thiel D, Jegasothy BV, Ackerman CD, Todo S, Fung JJ, Thomson AW, and Starzl TE (1991). FK 506: A new therapeutic agent for severe recalcitrant psoriasis. Transplant Proc 23: 3322–3324.
3. Annunziato F, Cosmi L, Galli G, Beltrame C, Romagnani P, Manetti R, Romagnani S, and Maggi E (1999). Assessment of chemokine receptor expression by human Th1 and Th2 cells in vitro and in in vivo. J Leukoc Biol 65: 691–699.
4. Arvilommi AM, Salmi M, Kalimo K, and Jalkanen S (1996). Lymphocyte binding to vascular endothelium in inflamed skin revisited: A central role for vascular adhesion protein-1 (VAP-1). Eur J Immunol 26: 825–833.
5. Austin LM, Ozawa M, Kikuchi T, Walters IB, and Krueger JG (1999). The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: A type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 113: 752–759.
Cited by
188 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献